Strides Pharma Q2 Revenue Rises 17%, Ex-US Sales Surpass US

What happened

Strides Pharma Science reported Q2 FY27 consolidated revenue of Rs 14,297 million, up 17.1 per cent year-on-year, and record quarterly EBITDA of Rs 2,509 million. Ex-US revenue rose 31 per cent to Rs 6,963 million, surpassing US revenue of Rs 6,855 million for the first time.

Confirmed

Global impact / market context

Selling more outside the US reduces reliance on one market, which can steady revenue if US prices or rules change. However, EBITDA margin fell to 17.6 per cent from 19 per cent because input material, freight and operating costs rose, so higher sales did not fully carry through to profit.

Analyst inference

Investors often judge drug makers on where growth comes from and whether profit per sale holds up. Here sales grew faster than EBITDA, showing cost pressure. The shift toward Ex-US markets may change how investors weigh US product launches against broader geographic spread.

Analyst inference

What to watch

1. Three products were launched in the US during the quarter, and US revenue grew 9 per cent year-on-year, so watch whether new launches lift US sales in coming quarters. Confirmed
2. Watch whether management can ease higher input material, freight and operating costs, since these pushed EBITDA margin down to 17.6 per cent from 19 per cent a year earlier. Proposed
3. Watch whether Ex-US revenue keeps exceeding US revenue, because a lasting mix shift would make overall sales less dependent on the US business. Analyst inference

Evidence

• Original source link unavailable